We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative medicines targeting cell cycle, transcriptional regulation and DNA damage response molecules critical in oncogenesis/cancer progression. Cyclacel's lead transcriptional regulation program is evaluating a CDK inhibitor, CYC065 in CLL patients in combination with venetoclax. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive solid cancers. The safety/tolerability profile of CYC140, a Polo-like-kinase 1 inhibitor is being assessed in advanced cancer patients. Cyclacel envisions building a healthcare business focusing on an unmet medical need for patients in the hematology-oncology area.